DE60108130D1 - Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten - Google Patents
Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheitenInfo
- Publication number
- DE60108130D1 DE60108130D1 DE60108130T DE60108130T DE60108130D1 DE 60108130 D1 DE60108130 D1 DE 60108130D1 DE 60108130 T DE60108130 T DE 60108130T DE 60108130 T DE60108130 T DE 60108130T DE 60108130 D1 DE60108130 D1 DE 60108130D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- pharmaceutical compositions
- neurological diseases
- aryl substituted
- amines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US616743 | 2000-07-14 | ||
US09/616,743 US6432954B1 (en) | 2000-07-14 | 2000-07-14 | Pharmaceutical compositions and methods for use |
PCT/US2001/021872 WO2002005798A2 (en) | 2000-07-14 | 2001-07-11 | Pharmaceutical compositions for treating neurological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60108130D1 true DE60108130D1 (de) | 2005-02-03 |
DE60108130T2 DE60108130T2 (de) | 2006-02-23 |
Family
ID=24470778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60108130T Expired - Fee Related DE60108130T2 (de) | 2000-07-14 | 2001-07-11 | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten |
Country Status (16)
Country | Link |
---|---|
US (1) | US6432954B1 (de) |
EP (1) | EP1311265B1 (de) |
JP (1) | JP2004509851A (de) |
CN (2) | CN1468100A (de) |
AT (1) | ATE285773T1 (de) |
AU (2) | AU2002222909B2 (de) |
BR (1) | BR0112130A (de) |
CA (1) | CA2415901A1 (de) |
DE (1) | DE60108130T2 (de) |
HU (1) | HUP0301553A3 (de) |
IL (3) | IL153577A0 (de) |
NO (1) | NO20030155L (de) |
NZ (1) | NZ523606A (de) |
PL (1) | PL360532A1 (de) |
WO (1) | WO2002005798A2 (de) |
ZA (1) | ZA200300135B (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
WO2005102051A1 (de) * | 2004-04-21 | 2005-11-03 | Basf Aktiengesellschaft | Fungizide mischungen |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
WO2007134038A2 (en) * | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
AR062860A1 (es) * | 2006-09-15 | 2008-12-10 | Astrazeneca Ab | Combinaciones terapeuticas 482 |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
WO2009018373A2 (en) * | 2007-07-31 | 2009-02-05 | Targacept, Inc. | Transdermal administration of (2s) - (4e) -n-methyl-5- (3- ( 5-is0pr0p0xypyridin) yl) -4-penten-2-amine |
AU2011256866B2 (en) | 2010-05-20 | 2014-05-22 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1409551A (en) | 1972-04-14 | 1975-10-08 | Allen & Hanburys Ltd | Cyclopent a indene derivatives |
US4528290A (en) | 1984-01-30 | 1985-07-09 | Eli Lilly And Company | Stimulating dopamine D-1 receptors |
GB8606254D0 (en) | 1986-03-13 | 1986-04-16 | Wyeth John & Brother Ltd | Substituted pyrimidoindoles |
FR2664600B1 (fr) | 1990-07-16 | 1994-09-02 | Rhone Poulenc Sante | Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib. |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
ZA957746B (en) * | 1994-09-14 | 1996-07-25 | Lundbeck & Co As H | Carbamoyloxy amine compounds |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
JP3603177B2 (ja) * | 1998-03-26 | 2004-12-22 | 参天製薬株式会社 | 新規ウレア誘導体 |
ES2150353B1 (es) * | 1998-04-15 | 2001-07-01 | Esteve Labor Dr | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos. |
CA2709735A1 (en) * | 1998-06-16 | 1999-12-23 | Targacept, Inc. | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
DE10032456A1 (de) * | 2000-07-04 | 2002-01-31 | Lohmann Therapie Syst Lts | Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen |
US6743812B1 (en) * | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
-
2000
- 2000-07-14 US US09/616,743 patent/US6432954B1/en not_active Expired - Fee Related
-
2001
- 2001-07-11 NZ NZ523606A patent/NZ523606A/xx unknown
- 2001-07-11 CA CA002415901A patent/CA2415901A1/en not_active Abandoned
- 2001-07-11 AU AU2002222909A patent/AU2002222909B2/en not_active Ceased
- 2001-07-11 AT AT01984212T patent/ATE285773T1/de not_active IP Right Cessation
- 2001-07-11 BR BR0112130-8A patent/BR0112130A/pt not_active Application Discontinuation
- 2001-07-11 PL PL01360532A patent/PL360532A1/xx not_active Application Discontinuation
- 2001-07-11 EP EP01984212A patent/EP1311265B1/de not_active Expired - Lifetime
- 2001-07-11 AU AU2290902A patent/AU2290902A/xx active Pending
- 2001-07-11 HU HU0301553A patent/HUP0301553A3/hu unknown
- 2001-07-11 DE DE60108130T patent/DE60108130T2/de not_active Expired - Fee Related
- 2001-07-11 CN CNA018127924A patent/CN1468100A/zh active Pending
- 2001-07-11 IL IL15357701A patent/IL153577A0/xx unknown
- 2001-07-11 WO PCT/US2001/021872 patent/WO2002005798A2/en active IP Right Grant
- 2001-07-11 CN CNA2005100541592A patent/CN1680326A/zh active Pending
- 2001-07-11 JP JP2002511731A patent/JP2004509851A/ja active Pending
-
2002
- 2002-12-22 IL IL153577A patent/IL153577A/en not_active IP Right Cessation
-
2003
- 2003-01-06 ZA ZA200300135A patent/ZA200300135B/en unknown
- 2003-01-13 NO NO20030155A patent/NO20030155L/no not_active Application Discontinuation
-
2008
- 2008-06-18 IL IL192287A patent/IL192287A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200300135B (en) | 2004-04-06 |
WO2002005798A2 (en) | 2002-01-24 |
CA2415901A1 (en) | 2002-01-24 |
EP1311265A2 (de) | 2003-05-21 |
DE60108130T2 (de) | 2006-02-23 |
NZ523606A (en) | 2004-12-24 |
JP2004509851A (ja) | 2004-04-02 |
US6432954B1 (en) | 2002-08-13 |
PL360532A1 (en) | 2004-09-06 |
EP1311265B1 (de) | 2004-12-29 |
CN1680326A (zh) | 2005-10-12 |
NO20030155L (no) | 2003-03-13 |
AU2290902A (en) | 2002-01-30 |
BR0112130A (pt) | 2003-09-02 |
IL153577A0 (en) | 2003-07-06 |
IL192287A0 (en) | 2008-12-29 |
AU2002222909B2 (en) | 2005-12-15 |
IL153577A (en) | 2009-07-20 |
HUP0301553A2 (hu) | 2003-08-28 |
CN1468100A (zh) | 2004-01-14 |
ATE285773T1 (de) | 2005-01-15 |
HUP0301553A3 (en) | 2005-05-30 |
NO20030155D0 (no) | 2003-01-13 |
WO2002005798A3 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
ATE416164T1 (de) | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
DE602004030222D1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
HUP0203325A2 (hu) | Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
ATE451368T1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
ATE198550T1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
ATE334120T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
ATE499933T1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
WO2002005801A3 (en) | Compositions containing diacyltartaric salts of (e)-metanicotine | |
DE69926794D1 (de) | Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen | |
HUP0103712A2 (hu) | Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk | |
DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |